Metagenomi Therapeutics, Inc. Operating Lease, Expense
Metagenomi Therapeutics, Inc. (MGX) reported Operating Lease, Expense of $2.69 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-10
- Metagenomi Therapeutics, Inc. operating lease, expense for the quarter ending 2026-06-30 was $1.35M, a 2.59% decline year-over-year.
- Metagenomi Therapeutics, Inc. operating lease, expense for the quarter ending 2026-03-31 was $1.33M, a 4.87% increase year-over-year.
- Metagenomi Therapeutics, Inc. operating lease, expense for the quarter ending 2025-12-31 was $1.38M, a 14.03% increase year-over-year.
- Metagenomi Therapeutics, Inc. operating lease, expense for the quarter ending 2025-09-30 was $1.27M, a 8.90% increase year-over-year.
- Metagenomi Therapeutics, Inc. operating lease, expense for fiscal 2025 was $5.32M, a 14.51% increase from fiscal 2024.
- Metagenomi Therapeutics, Inc. operating lease, expense for fiscal 2024 was $4.64M, a 10.39% increase from fiscal 2023.
- Metagenomi Therapeutics, Inc. operating lease, expense for fiscal 2023 was $4.21M.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $2.69M 10-Q · filed 2026-08-10 | $4.07M derived: sum of 3 quarters · filed 2026-08-10 | $5.34M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $1.33M 10-Q · filed 2026-05-11 | $2.72M derived: sum of 2 quarters · filed 2026-05-11 | $3.99M derived: sum of 3 quarters · filed 2026-05-11 | $5.38M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.65M derived: sum of 2 quarters · filed 2026-03-05 | $4.04M derived: sum of 3 quarters · filed 2026-08-10 | $5.32M 10-K · filed 2026-03-05 |
| 2025-09-30 | $1.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.66M derived: sum of 2 quarters · filed 2026-08-10 | $3.94M 10-Q · filed 2025-11-12 | $5.15M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $1.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $2.66M 10-Q · filed 2026-08-10 | $3.88M derived: sum of 3 quarters · filed 2026-08-10 | $5.04M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $1.27M 10-Q · filed 2026-05-11 | $2.48M derived: sum of 2 quarters · filed 2026-05-11 | $3.65M derived: sum of 3 quarters · filed 2026-05-11 | $4.79M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.38M derived: sum of 2 quarters · filed 2026-03-05 | $3.52M derived: sum of 3 quarters · filed 2026-03-05 | $4.64M 10-K · filed 2026-03-05 |
| 2024-09-30 | $1.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.31M derived: sum of 2 quarters · filed 2025-11-12 | $3.43M 10-Q · filed 2025-11-12 | $4.53M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $2.26M 10-Q · filed 2025-08-12 | $3.36M derived: sum of 3 quarters · filed 2025-08-12 | $4.43M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $1.13M 10-Q · filed 2025-05-13 | $2.23M derived: sum of 2 quarters · filed 2025-05-13 | $3.29M derived: sum of 3 quarters · filed 2025-05-13 | $4.35M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $2.17M derived: sum of 2 quarters · filed 2025-03-17 | $3.22M derived: sum of 3 quarters · filed 2025-03-17 | $4.21M 10-K · filed 2025-03-17 |
| 2023-09-30 | $1.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $2.12M derived: sum of 2 quarters · filed 2024-11-13 | $3.11M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $2.04M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $983.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |